Dignify Therapeutics
CompanyUnited States
Dignify Therapeutics develops one asset, in phase 1 (DTI-117 in neurogenic bowel dysfunction). Mostly other; based in the United States.
- 1
- Asset
- Furthest stage
- Phase 1
- 0
- Trials
- 0
- Signals
Pipeline
1Phase 1, Other, neurogenic bowel dysfunction
Full company profiles: pipeline, trials, funding and people.